Organization
Oslo University Hospital, Division of Cancer Medicine, Oslo, Norway
9 abstracts
Abstract
Single point of entry to the European precision cancer medicine trial network PRIME-ROSE.Org: Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital and University of Oslo, Oslo, Norway, National Cancer Institute, Vilnius, Lithuania, The Swedish Institute for Health Economics, Lund, Sweden, Oslo University Hospital, Division of Cancer Medicine, Oslo, Norway, Comprehensive Cancer Center, Helsinki University Hospital, Helsinki, Finland,
Abstract
Zilovertamab vedotin (MK 2140) in relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): Early results from the phase 2 waveLINE-004 study.Org: University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, Indiana Blood and & Marrow Transplantation, Franciscan Health, Karmanos Cancer Institute, Oslo University Hospital, Division of Cancer Medicine, Oslo, Norway, Sungkyunkwan University School of Medicine, Samsung Medical Center,
Abstract
15-month safety and efficacy data after intraperitoneal treatment with 224Radium-labelled microparticles after CRS-HIPEC for peritoneal metastasis from colorectal cancer.Org: Norwegian Radium Hospital, Department of Surgical Sciences, Uppsala University and Akademiska sjukhuset-Blod-och tumorsjukdomar, Oslo University Hospital, Division of Cancer Medicine, Oslo, Norway, University Hospital 12 de Octubre,
Abstract
Alternating short-course oxaliplatin-based chemotherapy and nivolumab as first-line treatment of patients with abdominal metastases from microsatellite-stable (MSS) colorectal cancer (CRC): A randomized phase 2 trial.Org: Akershus University Hospital (Ahus), Lorenskog, Sørlandet Hospital, Kristiansand, St.Olav's University Hospital,
Abstract
3D volume growth rate evaluation in the EORTC-BTG-1320 clinical trial for recurrent WHO grade 2 and 3 meningiomas.Org: Aix-Marseille University CHU Timone, APHM, Service d'Oncologie Multidisciplinaire & Innovations Thérapeutiques, CNRS UMR 5309-INSERM U1209, INP, Inst Neurophysiopathol,
Abstract
Randomized phase 2 study of nab-paclitaxel and gemcitabine with or without tocilizumab as first-line treatment in patients with advanced pancreatic cancer (PACTO).Org: Copenhagen University Hospital - Herlev and Gentofte, Oslo University Hospital, Division of Cancer Medicine, Oslo, Norway, Indiana University School of Medicine and Regenstrief Institute, Indianapolis, IN,
Abstract
IMPRESS-Norway: Improving public cancer care by implementing precision cancer medicine in Norway.Org: University of Oslo, Division of Cancer Medicine, Oslo University Hospital, Division of Cancer Medicine, Oslo, Norway, Institute of Clinical Medicine, Oslo Universitetssykehus, Oslo, Norway,
Abstract
BORTEM-17: A phase IB/II single arm, multicentre study investigating the efficacy of sequential bortezomib and temozolomide in recurrent GBM with unmethylated MGMT promoter—The results of an interim analysis.Org: Haukeland University Hospital, Department of Oncology and Haematology, Division of Oncology, University Hospital of Modena, Modena, Italy, Bergen, Norway, Institute for Cancer Genetics and Informatics, Oslo University Hospital, Oslo, Norway, Oslo University Hospital, Division of Cancer Medicine, Oslo, Norway,
Abstract
ASSOCIATION OF A LOWER BODY-MASS INDEX WITH THE PRESENCE OF ILD IN SSc PATIENTS – A DERIVATION PREDICTION STUDY USING DECISION TREE-BASED ALGORITHMSOrg: University Hospital Zurich, University of Zurich / ETH Zurich, Department of Rheumatology, University Hospital Düsseldorf, Medical Faculty of Heinrich Heine University, Düsseldorf, Germany, Zurich, Switzerland, University of Florence, AOUC,